Breadcrumb

Categories Navigation

Asset Publisher

null Infectious Diseases Unit
Hospital Universitario Reina Sofía (Córdoba)

Description

The Infectious Diseases Unit at the Reina Sofía University Hospital in Cordoba is under the leadership of Antonio Rivero Román. Our research group studies infection diseases using two main approaches:

  • Clinical and epidemiological studies (including clinical trials). Our objective in these studies is to identify and differentiate risk factors, clinical features and the efficacy/safety of new treatments in order to improve the prognosis of infectious diseases.
  • Pathogenesis studies for use in developing specific clinical strategies. The most relevant are our studies on immunopathology.

All our studies start by identifying a clinical problem, which we try to solve using an experimental approach. Our aim is for our scientific findings to have an impact on healthcare solutions and to improve disease prognosis (translational research).

Our specific lines of research are as follows:

  1. HIV infection: Our lines of research concerning the natural history of HIV infection include
    • Fatty liver disease in HIV-infected patients
    • Resistance to HIV infection
    • Innate immunity against HIV
    • The evaluation of new therapeutic regimens for the treatment of HIV infection
  2. HIV and coinfection with hepatotropic viruses: The research in this section encompass 8 main lines:
    • Epidemiology of HIV-HCV co-infection in Andalusia
    • Epidemiology of HEV infection in HIV-infected patients
    • Evaluation of routes of HEV transmission in HIV-infected patients
    • The natural history of fibrosis/cirrhosis of the liver in HCV-infected patients
    • Clinical implications and complications of HEV infection in HIV-infected patients
    • Evaluation of new therapeutic regimens for the treatment of HCV infection in HIV coinfected patients
    • Optimization of HCV treatment in patients co-infected with HIV
    • Prediction of response to HCV treatment

Related Assets

Members

Antonio Rivero
Teresa Brieva
Ángela Camacho
Mario Frías
Isabel Machuca
José Peña
Antonio Rivero-Juarez

Related Assets

Related Assets

Publications

  • A 24-week treatment strategy with Peg-IFN/RBV in HIV/HCV genotype 3 co-infected patients who achieveda rapid virological response results in a high sustained virological response rate. 
    Rivero-Juarez A, López-Cortés LF, Camacho A, Mira JA, Téllez F, Marquez M, Merino D, Pineda JA, Rivero A; on behalf of the Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR), part of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).  Clin Infect Dis. 2014; 58(1): 130-133. DOI: 10.1093/cid/cit653. PMID: 24065317 IF: 8,736 1º Cuartil 1º Decil INFECTIOUS DISEASES 2/83 
  • Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirina in HIV/HCV co-infected patients with genotype 1 or 4. 
    Rivero-Juárez A, Camacho A, Pérez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A.  J Antimicrob Chemother 2012; 67(1): 202-205. DOI: 10.1093/jac/dkr439 PMID: 21990051 IF: 5,439 1º Cuartil 1º Decil INFECTIOUS DISEASES 6/72 
  • Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV. 
    Rivero-Juarez A, Lopez-Cortes LF, Girón-Gonzalez JA, Pineda JA, Rivero A and Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas  Lancet Infectious Disease 2014 Jan;14(1):13-14 DOI: 10.1016/S1473-3099(13)70359-1. PMID: 24355031 IF: 19,864 1º Cuartil 1º Decil INFECTIOUS DISEASE 1/83 
  • Hepatitis E virus infection in anti-HEV IgG-carryinfing patients after successful HCV treatment: reactivation or reinfection? 
    Rivero-Juarez A, Frías M, Lopez-Lopez P, Risalde MA, Brieva T, Machuca I, Camacho A, Martínez-Peinado A, Gómez-Villamandos JC, Rivero A.  Clin Infect Dis. 2017. 64(7): 964-966 DOI: 10.1093/cid/cix004. PMID: 28077520 IF: 8,216 1º Cuartil 1º Decil INFECTIOUS DISEASES 4/84 
  • High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients. 
    Rivero-Juárez A, Martínez-Dueñas L, Martínez-Peinado A, Camacho A, Cifuentes C, Gordón A, Frías M, Torre-Cisneros J, Pineda JA, Rivero A.  J Infect. 2015; 70(6): 624-630. DOI: 10.1016/j.jinf.2014.10.016. PMID: 25452042 IF: 4,201 1º Cuartil 2º Decil INFECTIOUS DISEASES 16/84 
  • HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy. 
    Frías M, Rodríguez-Cano D, Cuenca-López F, Macías J, Gordon A, Manzanares-Martín B, Pineda JA, Camacho Á, Torre-Cisneros J, Peña J, Rivero-Juárez A, Rivero A.  Pharmacogenomics J. 2016. DOI: 10.1038/tpj.2016.42. PMID: 27241060 IF: 3,815 1º Cuartil 3º Decil PHARMACOLOGY & PHARMACY 51/256 
  • LDLr Genotype Modifies the Impact of IL28B on HCV Viral Kinetics after the First Weeks of Treatment with PEG-IFN/RBV in HIV/HCV Patients. 
    Rivero-Juarez A, Camacho A, Caruz A, Neukam K, Gonzalez R, Di Lello FA, Perez-Camacho I, Mesa P, Torre-Cisneros J, Peña J, Pineda JA, Rivero A.  AIDS. 2012; 26(8): 1009-1015. DOI: 10.1097/QAD.0b013e3283528b1c PMID: 22382144 IF: 6,557 1º Cuartil 1º Decil INFECTIOUS DISEASES 4/72 
  • Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy. 
    Frias M, Rivero-Juárez A, Tellez F, Pérez-Perez M, Camacho A, Machuca I, Lorenzo-Moncada S, López-López P, Rivero A, Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).  PLoS One. 2017; 12(5): e0177141. DOI: 10.1371/journal.pone.0177141. ECollection 2017. PMID:28472191 IF: 2,806 1º Cuartil 3º Decil MULTIDISCIPLINARY SCIENCES 15/64 
  • Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. 
    Rivero-Juarez A, Neukam K, Labarga P, Camacho A, Macias J, Barreiro P, Torre-Cisneros J, Pineda JA, Soriano V, Rivero A.  J Infect. 2014; 68(4): 372-377. DOI: 10.1016/j.jinf.2013.11.009. PMID: 24269677 IF: 4,382 1º Cuartil 3º Decil INFECTIOUS DISEASES 13/83 
  • The IL28B effect on HCV kinetics of among HIV patients after the first weeks of Peg-IFN/RBV treatment varies according to HCV-1 subtype. 
    Rivero-Juarez A, Lopez-Cortes LF, Camacho A, Caruz A, Torres-Cornejo A, Martínez-Dueñas L, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.  AIDS. 2013; 27(12): 1941-1947. DOI:10.1097/QAD.0b013e328360ea1e PMID: 23917425 IF: 5,554 1º Cuartil 1º Decil INFECTIOUS DISEASES 7/78 

Related Assets

Network